Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

UNCOVERED: Ars pharma urges fda to delay approval of aquestive s allergic reaction treatment | History Defined

Silver,Spring,,Md,,Usa,-,June,25,,2022:,The,Fda

ARS Pharmaceuticals Inc. (NASDAQ:SPRY) filed a petition Monday urging the FDA to delay approval of Aquestive Therapeutics Inc.'s (NASDAQ:AQST) experimental epinephrine treatment, citing safety, dosing, and real-world use concerns.

The filing requests that the FDA withhold approval of AQST-109, a sublingual film branded as Anaphylm. If cleared, ARS wants a boxed warning highlighting potential cardiovascular risks.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.